Clinical trials: Acute Schizophrenia
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Schizophrenia
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
- Trial name
- NAC (NCT01232790)
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Schizophrenia
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up.
- Trial name
- NCT00404573
- Testing
- RGH-188
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Forest Laboratories
Schizophrenia
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose…
- Trial name
- RECONNECT-S (NCT01544608)
- Where
- 7 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,076 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia…
- Trial name
- NCT01541371
- Testing
- Paliperidone ER
- Volunteers
- 405 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia
RECONNECT-S ALPHA is a multicentre study to observe the management of schizophrenic patients who are hospitalized due to an acutely agitated psychotic episode.
- Trial name
- RECONNECT-S (NCT01394601)
- Where
- 8 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Schizophrenia
Art Therapy in Acute Schizophrenia
Randomised, controlled, single-blinded pilot study to assess the efficacy of psychodynamic art therapy in a sample of hospitalized, (sub)acutely psychotic patients with a diagnosis of schizophrenia compared to a group of patients…
- Trial name
- KUSS (NCT01622166)
- Testing
- psychodynamic art therapy
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00549718
- Testing
- Lurasidone HCl
- Where
- 48 sites in United States, France and 5 more
- Volunteers
- 489 people
- Sponsor
- Sumitomo Pharma America, Inc.
Psychosis
Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation
The overall aim of the proposed study is to determine the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted nurse-led, community-based rehabilitation treatment model for community-dwelling…
- Trial name
- ENHANCE (NCT06080477)
- Testing
- Enhanced Usual Care, Adapted ENHANCE Intervention
- Where
- Malawi
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in participants with an acute exacerbation of schizophrenia.
- Trial name
- NCT01098110
- Testing
- Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 532 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Cardio Risk of Acute Schizophrenia Olanzapine Duke
Primary Objective: To compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk (as estimated by elevation in non-HDL cholesterol levels) during the treatment…
- Trial name
- CRASOD (NCT00672464)
- Testing
- Olanzapine, Metformin, Simvastatin
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acute Psychotic Episode, Schizophrenia
Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
- Trial name
- NCT01491412
- Where
- 14 sites in Hungary, Latvia and 1 more
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia.
- Trial name
- NCT00148590
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- M. Schaefer, MD
Schizophrenia, Psychosis
Study of Immunotherapy in Autoantibody Positive Psychosis
Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them, often involving hallucinations or delusions.
- Conditions
- Schizophrenia, Psychosis, Auto Immune Disorders
- Trial name
- SINAPPS-1 (NCT02449746)
- Testing
- Plasma Exchange, Intravenous immunoglobulin
- Where
- 5 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Cambridge
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study. After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy…
- Trial name
- NCT00859872
- Testing
- risperidone oral solution, haloperidol
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Central South University